Publication:
National safety data of post-marketing use of omalizumab in severe persistent asthma in Turkey

Simple item page
dc.contributor.authorDursun, Adile Berna
dc.contributor.authorBavbek, Sevim
dc.contributor.authorMısırlıgil, Zeynep
dc.contributor.authorErdener, F.
dc.contributor.authorBüyüköztürk, Suna
dc.contributor.authorAydın, Ömür
dc.contributor.authorGemicioğlu, Bilun
dc.contributor.authorBayrak, P.
dc.contributor.authorErkekol, Ferda Öner
dc.contributor.authorYıldırım, Zeki
dc.contributor.authorÇilli, Aykut
dc.contributor.authorBoz, Bingol A.
dc.contributor.authorAlpaydın, Özgen A.
dc.contributor.authorKarakoç, Bingol G.
dc.contributor.authorGörgüner, Metin
dc.contributor.authorKarakaya, Gül
dc.contributor.authorIşık, Rüveyda
dc.contributor.authorBakırtaş, Arzu
dc.contributor.buuauthorSapan, Nihat
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentÇocuk Sağlığı ve Hastalıkları Ana Bilim Dalı
dc.date.accessioned2022-03-17T12:32:00Z
dc.date.available2022-03-17T12:32:00Z
dc.date.issued2011-06
dc.descriptionBu çalışma, 11-15 Haziran 2011 tarihleri arasında İstanbul[Türkiye]’da düzenlenen 30th Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI)’da bildiri olarak sunulmuştur.
dc.description.sponsorshipEuropean Acad Allergy & Clin Immunol (EAACI)
dc.identifier.citationDursun, A. vd. (2011). "National safety data of post-marketing use of omalizumab in severe persistent asthma in Turkey". Allergy, 66(Supplement 94), Special Issue SI, 675-676.
dc.identifier.endpage676
dc.identifier.issn0105-4538
dc.identifier.issn1398-9995
dc.identifier.issueSupplement 94
dc.identifier.startpage675
dc.identifier.urihttp://hdl.handle.net/11452/25149
dc.identifier.volume66
dc.identifier.wos000329462204080
dc.indexed.wosSCIE
dc.indexed.wosCPCIS
dc.language.isoen
dc.publisherWiley
dc.relation.collaborationSanayi
dc.relation.collaborationYurt içi
dc.relation.journalAllergy
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAllergy
dc.subjectImmunology
dc.subject.wosAllergy
dc.subject.wosImmunology
dc.titleNational safety data of post-marketing use of omalizumab in severe persistent asthma in Turkey
dc.typeMeeting Abstract
dc.wos.quartileQ1
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalı
local.indexed.atWOS

Files

License bundle

Now showing 1 - 1 of 1
Placeholder
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

İndeksli Yayınlar / Indexed Publications